Skip to main content

Table 4 DFS Multivariate Analysis

From: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation

Outcome

Hazard Ratio (95% CI)

P-value

NLR

 < 4

ref

0.14

 ≥ 4

1.19 (0.95–1.50)

 

PLR

 < 150

ref

0.71

 ≥ 150

0.96 (0.76–1.21)

 

Pre-treatment CEA

 < 5 ng/ml

ref

< 0.01

 ≥ 5 ng/ml

1.66 (1.34–2.05)

 

 Unknown

1.85 (1.37–2.51)

Clinical stage

0.01

 II

ref

 

 III

1.30 (1.02–1.65)

 Unknown

2.46 (1.24–4.90)

Hemoglobin

0.99 (0.99–1.00)

0.02

  1. CEA Carcinoembryonic antigen, DFS Disease-free survival, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us